Loading...
•
Mar 31, 2022
EyePoint Pharmaceuticals Q1 2022 Earnings Report
Announced first quarter 2022 financial results and highlighted recent corporate developments.
Key Takeaways
EyePoint Pharmaceuticals reported a strong first quarter with $9.0 million in net product revenue, a 32% increase from the first quarter of last year. The company is well-capitalized to continue advancing its pipeline, including two expected Phase 2 clinical trial initiations of EYP-1901 in wet AMD in Q3 and in NPDR later in the second half of 2022.
Presented positive eight-month safety and efficacy data from ongoing DAVIO Phase 1 clinical trial for EYP-1901 in wet age-related macular degeneration (wet AMD).
Announced EYP-1901 license to Betta Pharmaceuticals, to develop and commercialize EYP-1901 in China, Hong Kong, Macau and Taiwan.
Net product revenues of $9.0 million versus $6.8 million in Q1 2021, a 32% increase.
Management to host a conference call and webcast today at 8:30 a.m. ET.
Revenue by Segment
Forward Guidance
We expect the cash and investments on hand on March 31, 2022 and expected net cash inflows from our product sales will enable us to fund our current and planned operations into the second half of 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...